Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

Radiation and chemo combo tackles advanced non-small cell lung cancer

A new study led by researchers from the UCLA Health Jonsson Comprehensive Cancer Center shows that using high doses of radiation while integrating an ablative radiotherapy technique called stereotactic ablative radiotherapy (SABR) concurrently with chemotherapy is safe and effective in treating people with locally advanced non-small cell lung cancer that is not suitable for surgery.

11 Jan 2024

Breakthrough drug halts lung cancer and brain metastases

D'Or Institute for Research and Education (IDOR) played an important role in the phase III LIBRETTO-431 multicenter study, which evaluated the efficacy and safety of selpercatinib compared to control treatment, which consisted of platinum-based chemotherapy associated or not with pembrolizumab (immune checkpoint inhibitor) in non-small cell lung cancer (NSCLC).

5 Jan 2024

Novel PET tracer accurately detects common cancer mutation for tailored treatment

A novel PET imaging tracer has been proven to safely and effectively detect a common cancer gene mutation that is an important molecular marker for tumor-targeted therapy.

2 Jan 2024

Organoid study opens new avenues in pulmonary neuroendocrine cancer therapy

Researchers performed a molecular analysis of neuroendocrine neoplasm (NEN) patient-derived tumor organoids (PDTOs) and their parental neoplasms.

13 Dec 2023

Blocking an allergy pathway unleashes antitumor immunity in mouse models of non-small cell lung cancer

Researchers at the Icahn School of Medicine at Mount Sinai have identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of non-small cell lung cancer (NSCLC).

6 Dec 2023

Lung-MAP: A beacon of hope for lung cancer patients

The unique public-private partnership that for almost a decade has undergirded the first National Cancer Institute (NCI)-sponsored precision medicine clinical trial in lung cancer can serve as a model for future clinical research that is more rapid, innovative, and inclusive.

1 Dec 2023

Research paves way for clinical trials of existing drugs for brain metastasis

The largest review of papers for brain cancer that has spread from the lungs has found abnormalities in the brain cancer and for which licensed drugs could be clinically trialled to find out if they could treat the disease.

29 Nov 2023

AmoyDx and CST Expand Existing Partnership for the Development of Companion Diagnostics (CDx) to Support Precision Oncology

Cell Signaling Technology (CST), a life science biotechnology company and leading provider of antibodies, kits, and services, and Amoy Diagnostics Co., Ltd. (AmoyDx), a China-based innovative molecular diagnostics company in the field of precision oncology, announced today the expansion of their ongoing partnership for companion diagnostic (CDx) development in China.

From Cell Signaling Technology 23 Nov 2023

New study shows bivalent COVID-19 booster increases antibody response in lung cancer patients

Bivalent booster dose enhanced neutralization of Omicron XBB (sub)variants in non-small cell lung cancer (NSCLC) patients.

23 Nov 2023

Immunotherapy drug is safe and may benefit overall survival for patients with advanced NSCLC

For patients with advanced or metastatic non-small cell lung cancer (NSCLC) and limited performance status, an immune checkpoint inhibitor drug called durvalumab is safe and may benefit overall survival, according to a new eClinicalMedicine study by UPMC Hillman Cancer Center researchers.

21 Nov 2023

New understanding of lung cancer cells' 'memories' suggests novel treatment approach

A new understanding of lung cancer cells' "memories" suggests a new strategy for improving treatment, Memorial Sloan Kettering Cancer Center (MSK) researchers have found.

17 Nov 2023

New pathologic scoring system could help predict survival in lung cancer patients

A new pathologic scoring system that accurately assesses how much lung tumor is left after a patient receives presurgical cancer treatments can be used to predict survival, according to new research led by investigators at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center and the Mark Foundation Center for Advanced Genomics and Imaging at the Johns Hopkins University.

6 Nov 2023

Dato-DXd improves progression-free survival in patients with metastatic non-squamous NSCLC

Treatment with datopotamab deruxtecan (Dato-DXd), a novel Trop-2 directed antibody-drug conjugate, was found to significantly improve progression-free survival in patients with metastatic non-small cell lung cancer, an improvement that was primarily driven by patients with non-squamous tumors.

26 Oct 2023

Perioperative durvalumab may change standard-of-care for patients with resectable lung cancer

A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone for patients with operable non-small cell lung cancer (NSCLC), according to results of a Phase III trial reported by researchers at The University of Texas MD Anderson Cancer Center.

24 Oct 2023

Lactobacillus iners in tumors: Driving chemoradiation resistance via lactate-induced metabolic rewiring

Investigating tumor and gut microbiome traits that impact chemoradiation therapy in patients with cervical cancer.

24 Oct 2023

Perioperative immunotherapy improves event-free survival in resectable early-stage lung cancer

Compared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy – given before and after surgery – significantly improved event-free survival (EFS) in patients with resectable early-stage non-small cell lung cancer (NSCLC).

22 Oct 2023

Air pollution linked to increased breast cancer risk in women

Women living and working in places with higher levels of fine particle air pollution are more likely to get breast cancer than those living and working in less polluted areas.

17 Oct 2023

New treatment options offer hope for patients with non-small cell lung cancer

More people with non-small cell lung cancer (NSCLC) are likely to benefit from new drugs that target molecular alterations in tumour cells, with less need for chemotherapy, following results of multiple landmark clinical trials reported for the first time in late-breaking presentations at the ESMO Congress 2023 (1-7).

17 Oct 2023

Moffitt Cancer Center researchers identify hidden target of ROS1 inhibitor lorlatinib

Targeted cancer drugs are widely used because of their ability to inhibit specific proteins involved in cancer development with fewer side effects compared to chemotherapy drugs.

16 Oct 2023

Nongenetic mechanisms play a role in lung cancer treatment resistance

In a recent study led by Ravi Salgia, M.D., Ph.D., the Arthur & Rosalie Kaplan Chair in Medical Oncology, a team of researchers from City of Hope, one of the largest cancer research and treatment organizations in the United States, and other institutions found that nongenetic mechanisms are important in lung cancer patients who develop a resistance to one cancer therapy.

13 Oct 2023